Nature Communications (Sep 2021)
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
- Johannes Brägelmann,
- Carina Lorenz,
- Sven Borchmann,
- Kazuya Nishii,
- Julia Wegner,
- Lydia Meder,
- Jenny Ostendorp,
- David F. Ast,
- Alena Heimsoeth,
- Takamasa Nakasuka,
- Atsuko Hirabae,
- Sachi Okawa,
- Marcel A. Dammert,
- Dennis Plenker,
- Sebastian Klein,
- Philipp Lohneis,
- Jianing Gu,
- Laura K. Godfrey,
- Jan Forster,
- Marija Trajkovic-Arsic,
- Thomas Zillinger,
- Mareike Haarmann,
- Alexander Quaas,
- Stefanie Lennartz,
- Marcel Schmiel,
- Joshua D’Rozario,
- Emily S. Thomas,
- Henry Li,
- Clemens A. Schmitt,
- Julie George,
- Roman K. Thomas,
- Silvia von Karstedt,
- Gunther Hartmann,
- Reinhard Büttner,
- Roland T. Ullrich,
- Jens T. Siveke,
- Kadoaki Ohashi,
- Martin Schlee,
- Martin L. Sos
Affiliations
- Johannes Brägelmann
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Carina Lorenz
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Sven Borchmann
- Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Kazuya Nishii
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Julia Wegner
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn
- Lydia Meder
- Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Jenny Ostendorp
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- David F. Ast
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Alena Heimsoeth
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Takamasa Nakasuka
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Atsuko Hirabae
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Sachi Okawa
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Marcel A. Dammert
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Dennis Plenker
- Cold Spring Harbor Laboratory
- Sebastian Klein
- Else-Kröner-Forschungskolleg Clonal Evolution in Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Philipp Lohneis
- Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Jianing Gu
- Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen
- Laura K. Godfrey
- Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen
- Jan Forster
- Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ
- Marija Trajkovic-Arsic
- Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen
- Thomas Zillinger
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn
- Mareike Haarmann
- Mildred Scheel School of Oncology Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Alexander Quaas
- Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Stefanie Lennartz
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Marcel Schmiel
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Joshua D’Rozario
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Emily S. Thomas
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Henry Li
- Crown Bioscience
- Clemens A. Schmitt
- Department of Hematology, Oncology and Tumor Immunology, Charité - University Medical Center, Virchow Campus, and Molekulares Krebsforschungszentrum
- Julie George
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Roman K. Thomas
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Silvia von Karstedt
- Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Gunther Hartmann
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn
- Reinhard Büttner
- Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Roland T. Ullrich
- Center for Molecular Medicine Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne
- Jens T. Siveke
- Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen
- Kadoaki Ohashi
- Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Martin Schlee
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn
- Martin L. Sos
- Molecular Pathology, Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne
- DOI
- https://doi.org/10.1038/s41467-021-25728-8
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 15
Abstract
Kinase inhibitors are widely used to treat cancer, however patients frequently develop resistance. Here, the authors investigate adaption mechanisms during drug persistence and show that stimulation of the innate immunity sensor RIG-I enhances cancer cell death when combined with kinase inhibition.
